Obstructive sleep apnea and intermittent hypoxia increase expression of dual specificity phosphatase 1

Atherosclerosis

Volumn 231, Issue 2, 2013, Pages 378-383

  Hoffmann, Michal S ^a,b   Singh, Prachi ^a   Wolk, Robert ^a,c   Narkiewicz, Krzysztof ^b   Somers, Virend K ^a  

^a MAYO CLINIC   (United States)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Dual specificity phosphatase 1; Intermittent hypoxia; Obstructive sleep apnea; Reactive oxygen species

Indexed keywords

BETA ACTIN; MANGANESE SUPEROXIDE DISMUTASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1;

ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DEOXYGENATION; EX VIVO STUDY; GENE EXPRESSION; GENETIC TRANSCRIPTION; GRANULOCYTE; HUMAN; HUMAN CELL; HYPOXEMIA; IN VITRO STUDY; INTERMITTENT HYPOXIA; LEUKOCYTE; MONONUCLEAR CELL; OXIDATIVE STRESS; OXYGEN SATURATION; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REOXYGENATION; RISK ASSESSMENT; SLEEP DISORDERED BREATHING; WAKEFULNESS; WESTERN BLOTTING;

DUAL SPECIFICITY PHOSPHATASE 1; INTERMITTENT HYPOXIA; OBSTRUCTIVE SLEEP APNEA; REACTIVE OXYGEN SPECIES;

ADULT; ANOXIA; BODY MASS INDEX; CASE-CONTROL STUDIES; CELLS, CULTURED; CORONARY VESSELS; DUAL SPECIFICITY PHOSPHATASE 1; ENDOTHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; MIDDLE AGED; OXYGEN; REACTIVE OXYGEN SPECIES; SLEEP APNEA, OBSTRUCTIVE; SUPEROXIDE DISMUTASE; TIME FACTORS;

EID: 84888094948     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.09.033     Document Type: Article

References (45)

1. Laderoute K.R., Mendonca H.L., Calaoagan J.M., et al. Mitogen-activated protein kinase phosphatase-1 (MKP-1) expression is induced by low oxygen conditions found in solid tumor microenvironments. A candidate MKP for the inactivation of hypoxia-inducible stress-activated protein kinase/c-Jun N-terminal protein kinase activity. JBiol Chem 1999, 274(18):12890-12897.
2. Seta K.A., Kim R., Kim H.W., et al. Hypoxia-induced regulation of MAPK phosphatase-1 as identified by subtractive suppression hybridization and cDNA microarray analysis. JBiol Chem 2001, 276(48):44405-44412.
3. Franklin C.C., Kraft A.S. Conditional expression of the mitogen-activated protein kinase (MAPK) phosphatase MKP-1 preferentially inhibits p38 MAPK and stress-activated protein kinase in U937 cells. JBiol Chem 1997, 272(27):16917-16923.
4. Hirsch D.D., Stork P.J. Mitogen-activated protein kinase phosphatases inactivate stress-activated protein kinase pathways invivo. JBiol Chem 1997, 272(7):4568-4575.
5. Young T., Palta M., Dempsey J., et al. The occurrence of sleep-disordered breathing among middle-aged adults. NEngl J Med 1993, 328(17):1230-1235.
6. Peppard P.E., Young T., Palta M., et al. Prospective study of the association between sleep-disordered breathing and hypertension. NEngl J Med 2000, 342(19):1378-1384.
7. Kuniyoshi F.H., Pusalavidyasagar S., Singh P., et al. Cardiovascular consequences of obstructive sleep apnoea. Indian J Med Res 2010, 131:196-205.
8. Mooe T., Rabben T., Wiklund U., et al. Sleep-disordered breathing in women: occurrence and association with coronary artery disease. Am J Med 1996, 101(3):251-256.
9. Mooe T., Rabben T., Wiklund U., et al. Sleep-disordered breathing in men with coronary artery disease. Chest 1996, 109(3):659-663.
10. Sert Kuniyoshi F.H., Singh P., Gami A.S., et al. Patients with obstructive sleep apnea exhibit impaired endothelial function after myocardial infarction. Chest 2011, 140(1):62-67.
11. Hung J., Whitford E.G., Parsons R.W., et al. Association of sleep apnoea with myocardial infarction in men. Lancet 1990, 336(8710):261-264.
12. Yaggi H.K., Concato J., Kernan W.N., et al. Obstructive sleep apnea as a risk factor for stroke and death. NEngl J Med 2005, 353(19):2034-2041.
13. Lavie L., Lavie P. Molecular mechanisms of cardiovascular disease in OSAHS: the oxidative stress link. Eur Respir J 2009, 33(6):1467-1484.
14. Punjabi N.M., Sorkin J.D., Katzel L.I., et al. Sleep-disordered breathing and insulin resistance in middle-aged and overweight men. Am J Respir Crit Care Med 2002, 165(5):677-682.
15. Harrison D.G., Guzik T.J., Lob H.E., et al. Inflammation, immunity, and hypertension. Hypertension 2011, 57(2):132-140.
16. Alzoghaibi M.A., Bahammam A.S. Lipid peroxides, superoxide dismutase and circulating IL-8 and GCP-2 in patients with severe obstructive sleep apnea: a pilot study. Sleep Breath=Schlaf & Atmung 2005, 9(3):119-126.
17. Zhang J., Veasey S. Making sense of oxidative stress in obstructive sleep apnea: mediator or distracter?. Front Neurol 2012, 3:179.
18. Svatikova A., Wolk R., Lerman L.O., et al. Oxidative stress in obstructive sleep apnoea. Eur Heart J 2005, 26(22):2435-2439.
19. Barcelo A., Miralles C., Barbe F., et al. Abnormal lipid peroxidation in patients with sleep apnoea. Eur Respir J Off J Eur Soc Clin Respir Physiol 2000, 16(4):644-647.
20. Barcelo A., Barbe F., de la Pena M., et al. Antioxidant status in patients with sleep apnoea and impact of continuous positive airway pressure treatment. Eur Respir J 2006, 27(4):756-760.
21. Itzhaki S., Dorchin H., Clark G., et al. The effects of 1-year treatment with a herbst mandibular advancement splint on obstructive sleep apnea, oxidative stress, and endothelial function. Chest 2007, 131(3):740-749.
22. Lavie L., Vishnevsky A., Lavie P. Evidence for lipid peroxidation in obstructive sleep apnea. Sleep 2004, 27(1):123-128.
23. Gozal D., Kheirandish-Gozal L. Cardiovascular morbidity in obstructive sleep apnea: oxidative stress, inflammation, and much more. Am J Respir Crit Care Med 2008, 177(4):369-375.
24. Hoffmann M.S., Singh P., Wolk R., et al. Microarray studies of genomic oxidative stress and cell cycle responses in obstructive sleep apnea. Antioxid Redox Signal 2007, 9(6):661-669.
25. Marrotte E.J., Chen D.D., Hakim J.S., et al. Manganese superoxide dismutase expression in endothelial progenitor cells accelerates wound healing in diabetic mice. JClin Invest 2010, 120(12):4207-4219.
26. Pardo M., Tirosh O. Protective signalling effect of manganese superoxide dismutase in hypoxia-reoxygenation of hepatocytes. Free Radic Res 2009, 43(12):1225-1239.
27. 2-induced apoptosis via MAP kinase-MKP-1 pathway. Free Radic Biol Med 2004, 36(8):985-993.
28. Bogoyevitch M.A., Gillespie-Brown J., Ketterman A.J., et al. Stimulation of the stress-activated mitogen-activated protein kinase subfamilies in perfused heart. p38/RK mitogen-activated protein kinases and c-Jun N-terminal kinases are activated by ischemia/reperfusion. Circ Res 1996, 79(2):162-173.
29. Armstrong S.C. Protein kinase activation and myocardial ischemia/reperfusion injury. Cardiovasc Res 2004, 61(3):427-436.
30. Hausenloy D.J., Yellon D.M. Survival kinases in ischemic preconditioning and postconditioning. Cardiovasc Res 2006, 70(2):240-253.
31. Dean J.L., Brook M., Clark A.R., et al. p38 mitogen-activated protein kinase regulates cyclooxygenase-2 mRNA stability and transcription in lipopolysaccharide-treated human monocytes. JBiol Chem 1999, 274(1):264-269.
32. Brook M., Sully G., Clark A.R., et al. Regulation of tumour necrosis factor alpha mRNA stability by the mitogen-activated protein kinase p38 signalling cascade. FEBS Lett 2000, 483(1):57-61.
33. Miyazawa K., Mori A., Miyata H., et al. Regulation of interleukin-1beta-induced interleukin-6 gene expression in human fibroblast-like synoviocytes by p38 mitogen-activated protein kinase. JBiol Chem 1998, 273(38):24832-24838.
34. Lasa M., Mahtani K.R., Finch A., et al. Regulation of cyclooxygenase 2 mRNA stability by the mitogen-activated protein kinase p38 signaling cascade. Mol Cell Biol 2000, 20(12):4265-4274.
35. Dyugovskaya L., Lavie P., Hirsh M., et al. Activated CD8+ T-lymphocytes in obstructive sleep apnoea. Eur Respir J Off J Eur Soc Clin Respir Physiol 2005, 25(5):820-828.
36. Dyugovskaya L., Lavie P., Lavie L. Increased adhesion molecules expression and production of reactive oxygen species in leukocytes of sleep apnea patients. Am J Respir Crit Care Med 2002, 165(7):934-939.
37. Hammer M., Mages J., Dietrich H., et al. Control of dual-specificity phosphatase-1 expression in activated macrophages by IL-10. Eur J Immunol 2005, 35(10):2991-3001.
38. Abraham S.M., Lawrence T., Kleiman A., et al. Antiinflammatory effects of dexamethasone are partly dependent on induction of dual specificity phosphatase 1. JExp Med 2006, 203(8):1883-1889.
39. Wadgaonkar R., Pierce J.W., Somnay K., et al. Regulation of c-Jun N-terminal kinase and p38 kinase pathways in endothelial cells. Am J Respir Cell Mol Biol 2004, 31(4):423-431.
40. Li M., Zhou J.Y., Ge Y., et al. The phosphatase MKP1 is a transcriptional target of p53 involved in cell cycle regulation. JBiol Chem 2003, 278(42):41059-41068.
41. Korhonen R., Turpeinen T., Taimi V., et al. Attenuation of the acute inflammatory response by dual specificity phosphatase 1 by inhibition of p38 MAP kinase. Mol Immunol 2011, 48(15-16):2059-2068.
42. McCollum L.T., Gallagher P.E., Ann Tallant E. Angiotensin-(1-7) attenuates angiotensin II-induced cardiac remodeling associated with upregulation of dual-specificity phosphatase 1. Am J Physiol Heart Circ Physiol 2012, 302(3):H801-H810.
43. Imaizumi S., Grijalva V., Priceman S., et al. Mitogen-activated protein kinase phosphatase-1 deficiency decreases atherosclerosis in apolipoprotein E null mice by reducing monocyte chemoattractant protein-1 levels. Mol Genet Metab 2010, 101(1):66-75.
44. Shen J.Z., Chandrasekharan U.M., Ashraf M.Z., et al. Lack of mitogen-activated protein kinase phosphatase-1 protects ApoE-null mice against atherosclerosis. Circ Res 2010, 106(5):902-910.
45. Reddy S.T., Nguyen J.T., Grijalva V., et al. Potential role for mitogen-activated protein kinase phosphatase-1 in the development of atherosclerotic lesions in mouse models. Arterioscler Thromb Vasc Biol 2004, 24(9):1676-1681.